Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel

Colloids and Surfaces B: Biointerfaces

Volumn 123, Issue , 2014, Pages 716-723

  Sun, Yanbin ^a   Yu, Bo ^b   Wang, Guoying ^c   Wu, Yongsheng ^d   Zhang, Xiaomin ^b   Chen, Yanmin ^d   Tang, Suoqing ^e   Yuan, Yuan ^c   Lee, Robert J ^f,g   Teng, Lesheng ^f   Xu, Shun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Biotech (Hangzhou) CoLtd   (China)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Mudanjiang Youbo Pharmaceutical CoLtd   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f JILIN UNIVERSITY   (China)

^g OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Drug delivery; Lung cancer; Nanoparticles; Paclitaxel; TPGS

Indexed keywords

AUTOMOBILE MANUFACTURE; BIOLOGICAL ORGANS; CELL CULTURE; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; EMULSIFICATION; PARTICLE SIZE; POLYMERS; TARGETED DRUG DELIVERY; TUMORS;

ETHANOL-WATER SYSTEM; INTRAVENOUS INJECTIONS; LUNG CANCER; NANOPARTICLE FORMULATION; NANOPRECIPITATION METHOD; PACLITAXEL; POLYMERIC NANOPARTICLES; TPGS;

NANOPARTICLES;

ALCOHOL; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; TOCOFERSOLAN; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; EMULSION; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRECIPITATION;

EID: 84915746329     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.10.007     Document Type: Article

References (28)

1. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N. Engl. J. Med. 1995, 332(15):1004-1014.
2. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R., Van Echo D.A., Von Hoff D.D., Leyland-Jones B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 1990, 8(7):1263-1268.
3. Sharma U.S., Balasubramanian S.V., Straubinger R.M. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci. 1995, 84(10):1223-1230.
4. Hennenfent K.L., Govindan R. Novel formulations of taxanes: a review old wine in a new bottle?. Ann. Oncol. 2006, 17(5):735-749.
5. Gaucher G., Marchessault R.H., Leroux J.C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J. Control. Release 2010, 143(1):2-12.
6. Surapaneni M.S., Das S.K., Das N.G. Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol. 2012, 623139. 10.5402/2012/623139.
7. Yared J.A., Tkaczuk K.H. Update on taxane development: new analogs and new formulations. Drug Des. Dev. Therapy 2012, 6:371-384.
8. Akhtar N., Ahad A., Khar R.K., Jaggi M., Aqil M., Iqbal Z., Ahmad F.J., Talegaonkar S. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin. Ther. Pat. 2011, 21(4):561-576.
9. Mora-Huertas C.E., Fessi H., Elaissari A. Polymer-based nanocapsules for drug delivery. Int. J. Pharm. 2010, 385(1-2):113-142.
10. Acharya S., SK S. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 2011, 63:170-183.
11. Markovsky E., Baabur-Cohen H., Eldar-Boock A., Omer L., Tiram G., Ferber S., Ofek P., Polyak D., Scomparin A., Satchi-Fainaro R. Administration, distribution, metabolism and elimination of polymer therapeutics. J. Control. Release 2012, 161(2):446-460.
12. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 2012, 161(2):505-522.
13. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release 2012, 164(2):138-144.
14. Taurin S., Nehoff H., Greish K. Anticancer nanomedicine and tumor vascular permeability: where is the missing link?. J. Control. Release 2012, 164(3):265-275.
15. Egusquiaguirre S.P., Igartua M., Hernandez R.M., Pedraz J.L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin. Transl. Oncol. 2012, 14(2):83-93.
16. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 2009, 136(1):21-29.
17. Wang Y., Guo M., Lu Y., Ding L.Y., Ron W.T., Liu Y.Q., Song F.F., Yu.S.Q. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnology 2012, 23(49):495103.
18. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (taxol). J. Control. Release 2002, 80(1-3):129-144.
19. Win K.Y., Feng.S.S. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d,l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 2006, 27(10):2285-2291.
20. Anton N., Benoit J.P., Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates - a review. J. Control. Release 2008, 128(3):185-199.
21. Zhang Z., Mei L., Feng S.S. Vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine (Lond.) 2012, 7(11):1645-1647.
22. Zhang Z., Tan S., Feng S.S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012, 33(19):4889-4906.
23. Guo Y., Luo J., Tan S., Otieno B.O., Zhang Z. The applications of vitamin E TPGS in drug delivery. Eur. J. Pharm. Sci. 2013, 49(2):175-186.
24. Bogman K., Erne-Brand F., Alsenz J., Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J. Pharm. Sci. 2003, 92(6):1250-1261.
25. Feng S.S., Zeng W., Teng Lim Y., Zhao L., Yin Win K., Oakley R., Hin Teoh S., Hang Lee R.C., Pan S. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomedicine (Lond.) 2007, 2(3):333-344.
26. Muthu M.S., Kulkarni S.A., Liu Y., Feng.S.S. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond.) 2012, 7(3):353-364.
27. Wang G., Yu B., Wu Y., Huang B., Yuan Y., Liu.C.S. Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel. Int. J. Pharm. 2013, 446(1-2):24-33.
28. Cheng F.Y., Wang S.P., Su C.H., Tsai T.L., Wu P.C., Shieh D.B., Chen J.H., Hsieh P.C., Yeh C.S. Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials 2008, 29(13):2104-2112.